209348-85-6Relevant academic research and scientific papers
Novel Spiropiperidine Compounds
-
Page/Page column 8, (2011/05/03)
A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.
Synthesis and structure based optimization of novel Akt inhibitors
Lippa, Blaise,Pan, Gonghua,Corbett, Matthew,Li, Chao,Kauffman, Goss S.,Pandit, Jayvardhan,Robinson, Shaughnessy,Wei, Liuqing,Kozina, Ekaterina,Marr, Eric S.,Borzillo, Gary,Knauth, Elisabeth,Barbacci-Tobin, Elsa G.,Vincent, Patrick,Troutman, Merin,Baker, Deborah,Rajamohan, Francis,Kakar, Shefali,Clark, Tracey,Morris, Joel
body text, p. 3359 - 3363 (2009/04/05)
Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced pot
TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS
-
Page/Page column 62-63, (2010/02/10)
This invention provides the compounds of formula (I), or its a pharmaceutically acceptable ester or amide of such compound, or a pharmaceutically acceptable salt thereof, wherein X1 is NH; R1, R2, R4 through Rs
ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST
-
Page/Page column 56, (2010/02/14)
This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein Ri and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxgen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.
Spiro-substituted azacycles as neurokinin antagonists
-
, (2008/06/13)
Disclosed are spiro-substituted azacycles of formula I are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compounds of formula I are shown to be neurokinin antagonists.
SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
, (2008/06/13)
The present invention is directed to spiro-substituted azacycles of the Formula 1: STR1 (wherein R 1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
